Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB) A Systematic Review and Delphi Consensus Statement
Pijnappel EN, Suurmeijer JA, Koerkamp BG, Kos M, Siveke JT, Salvia R, Ghaneh P, Van Eijck CHJ, Van Etten-Jamaludin FS, Abrams R, Brasiuniene B, Buechler MW, Casadei R, Van Laethem JL, Berlin J, Boku N, Conroy T, Golcher H, Sinn M, Neoptolemos JP, Van Tienhoven G, Besselink MG, Wilmink JW, Van Laarhoven HWM (2022)
Publication Type: Journal article, Review article
Publication year: 2022
Journal
DOI: 10.1001/jamaoncol.2022.0168
Abstract
IMPORTANCE Pancreatic cancer is the third most common cause of cancer death; however, randomized clinical trials (RCTs) of survival in patients with resectable pancreatic cancer lack mandatory measures for reporting baseline and prognostic factors, which hampers comparisons between outcome measures.
Authors with CRIS profile
Involved external institutions
Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra
Netherlands (NL)
Erasmus University Medical Center (MC)
Netherlands (NL)
Universität Duisburg-Essen (UDE)
Germany (DE)
University of Verona / Università degli Studi di Verona
Italy (IT)
The University of Liverpool
United Kingdom (GB)
Hadassah Medical Center / מרכז רפואי הדסה
Israel (IL)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Université libre de Bruxelles (ULB) / Free University of Brussels
Belgium (BE)
Vanderbilt University Medical Center
United States (USA) (US)
National Cancer Centre Singapore (NCCS)
Singapore (SG)
Institute Cancer De Lorraine - Alexis Vautrin
France (FR)
Charité - Universitätsmedizin Berlin
Germany (DE)
Netherlands (NL)
Erasmus University Medical Center (MC)
Netherlands (NL)
Universität Duisburg-Essen (UDE)
Germany (DE)
University of Verona / Università degli Studi di Verona
Italy (IT)
The University of Liverpool
United Kingdom (GB)
Hadassah Medical Center / מרכז רפואי הדסה
Israel (IL)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Université libre de Bruxelles (ULB) / Free University of Brussels
Belgium (BE)
Vanderbilt University Medical Center
United States (USA) (US)
National Cancer Centre Singapore (NCCS)
Singapore (SG)
Institute Cancer De Lorraine - Alexis Vautrin
France (FR)
Charité - Universitätsmedizin Berlin
Germany (DE)
How to cite
APA:
Pijnappel, E.N., Suurmeijer, J.A., Koerkamp, B.G., Kos, M., Siveke, J.T., Salvia, R.,... Van Laarhoven, H.W.M. (2022). Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB) A Systematic Review and Delphi Consensus Statement. JAMA Oncology. https://dx.doi.org/10.1001/jamaoncol.2022.0168
MLA:
Pijnappel, Esther N., et al. "Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB) A Systematic Review and Delphi Consensus Statement." JAMA Oncology (2022).
BibTeX: Download